News

Alcon has entered into a five-year collaborative research agreement with AstraZeneca, for the exclusive ophthalmic discovery and potential development rights to AstraZeneca’s compound library. Reportedly, the two companies

Schering-Plough has filed a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate in US, which is accepted for review by the FDA.

RTI Biologics has signed an expanded agreement with Davol, a subsidiary of CR Bard. Under the agreement, RTI will supply Tutoplast for exclusive worldwide distribution by Davol for

Cellceutix has completed acute toxicity studies in mice and rats with its Kevetrin. In these studies, Kevetrin showed no significant indications of toxicity. In the acute toxicity mouse

Takeda Global Research & Development Center has received notification from the FDA that it has extended the review of the New Drug Application (NDA) for the fixed-dose combination

Alcon has reported global sales revenue of $1.67 billion for the second quarter of 2009, a decrease of 3.4% compared to the second quarter of 2008. Net earnings

Profectus BioSciences has closed on a $5 million Series C venture financing. Current investor, Cross Atlantic Capital Partners led the round, which brings the total venture investment in

Peregrine and Affitech have entered into a licensing agreement for antibody therapeutic rights, under the Peregrine’s preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. As per terms of

Tobira has reported pharmacokinetic data and results from two phase I pharmacokinetic studies for TAK-652. It is an investigational compound being developed for the treatment of HIV. Reportedly,